Blog

After reaching the goal of 100,000 veterans cured of hepatitis C virus (HCV) in as few as two months, the Department of Veterans Affairs (VA) now includes in its contract with Echosens the FibroScan® 430 mini+ portable technology.

Diabetes is one of the leading causes of disability and death in the United States. One in 10 Americans have diabetes — more than 30 million people — and another 84 million adults are at high risk of developing Type 2 diabetes.

Physicians and administrators at some of the nation’s leading Federally Qualified Health Centers (FQHCs) now have the ability to quickly and easily assess liver health to better address the NAFLD epidemic

It’s startling to learn that over 30% of the U.S. population has some degree of non-alcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver and the most common type of liver disease in the Western world

A growing number of healthcare providers are adopting FibroScan, a non-invasive technology to examine patient’s liver at the point of care.

Taking a strong leadership position against the looming worldwide epidemic of liver disease, Echosens is dedicated to the assessment of chronic liver disease and positioned for exponential growth.

300 million people worldwide are unaware that they are living with viral hepatitis.

Hear from two of our global leaders, Dominique Legros and Jon Gingrich, how Echosens is poised for exceptional growth as we focus on the assessment of chronic liver disease against the looming worldwide epidemic of NAFLD.

After reaching the goal of 100,000 veterans cured of HCV, the Department of Veterans Affairs now includes the FibroScan mini+ portable technology in its contract

Echosens recently recruited Dominique Legros to lead the company as global CEO. Medgadget caught up with him to learn more about the company and his goals for its future.